QNCX: LAM-001 shows promise as a once-daily inhaled therapy for multiple high-need pulmonary diseases
LAM-001, a once-daily inhaled rapamycin, is advancing through clinical trials for BOS, PH-ILD, and SAPH, with key data readouts expected in 2027 and 2028. Early results show strong pulmonary delivery, low systemic exposure, and promising efficacy, positioning the asset for broad expansion in pulmon…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.